Simpson Thacher Represents Dealer Managers in $2.9 Billion Tender Offer by Roche
12.19.19
This is only gets display when printing
The Firm recently represented the dealer managers in connection with a tender offer by Roche Holdings, Inc. (“Roche”) to purchase for cash, for a maximum combined aggregate purchase price of $2.873 billion, the 7% Notes due 2039 issued by Roche and guaranteed by Roche Holding Ltd, a Swiss corporation (“Roche Holding”), the 3.35% Notes due 2024 issued by Roche and guaranteed by Roche Holding, the 3.25% Notes due 2023 issued by Roche and guaranteed by Roche Holding, the 3% Notes due 2025 issued by Roche and guaranteed by Roche Holding, the 2.875% Notes due 2021 issued by Roche and guaranteed by Roche Holding and the 5.25% Senior Notes due 2035 issued by Roche’s subsidiary, Genentech, Inc.
The Roche Group is a leading international research-focused healthcare group which is active in more than 100 countries. The Roche Group is the world’s leading supplier of in vitro diagnostics, the world’s largest biotech company and the world’s leading provider of cancer treatments.
The Simpson Thacher team for the transaction included Marisa Stavenas, Mark Brod and Camilla Johnson (Capital Markets); and Jon Cantor and Dmitry Zelik (Tax).